Literature DB >> 25597007

Synthesis and pharmacological evaluation of multifunctional tacrine derivatives against several disease pathways of AD.

Maria Digiacomo1, Ziwei Chen2, Shengnan Wang2, Annalina Lapucci1, Marco Macchia1, Xiaohong Yang2, Jiaqi Chu2, Yifan Han3, Rongbiao Pi4, Simona Rapposelli5.   

Abstract

A novel series of tacrine derivatives were designed and synthesized by combining caffeic acid (CA), ferulic acid (FA) and lipoic acid (LA) with tacrine. The antioxidant study revealed that all the hybrids have much more antioxidant capacities compared to CA. Among these compounds, 1b possessed a good ability to inhibit the β-amyloid protein (Aβ) self-aggregation, sub-micromole acetylcholinesterase (AChE)/butyrylcholinesterase (BuChE) inhibitory, modest BACE1 inhibitory. Moreover, compound 1b also was a DPPH radical scavenger and copper chelatory as well as had potent neuroprotective effects against glutamate-induced cell death with low toxicity in HT22 cells. Our findings suggest that the compound 1b might be a promising lead multi-targeted ligand and worthy of further developing for the therapy of Alzheimer's disease.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid protein; BACE1; Caffeic acid; Copper; Multi-targeted ligands; Tacrine

Mesh:

Substances:

Year:  2015        PMID: 25597007     DOI: 10.1016/j.bmcl.2014.12.084

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  6 in total

1.  4-Aminoquinoline-Based Adamantanes as Potential Anticholinesterase Agents in Symptomatic Treatment of Alzheimer's Disease.

Authors:  Katarina Komatović; Ana Matošević; Nataša Terzić-Jovanović; Suzana Žunec; Sandra Šegan; Mario Zlatović; Nikola Maraković; Anita Bosak; Dejan M Opsenica
Journal:  Pharmaceutics       Date:  2022-06-20       Impact factor: 6.525

Review 2.  Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer's Disease and Future Perspectives.

Authors:  Natália Chermont Dos Santos Moreira; Jéssica Ellen Barbosa de Freitas Lima; Marcelo Fiori Marchiori; Ivone Carvalho; Elza Tiemi Sakamoto-Hojo
Journal:  J Alzheimers Dis Rep       Date:  2022-04-18

Review 3.  Novel multitarget-directed tacrine derivatives as potential candidates for the treatment of Alzheimer's disease.

Authors:  Wen-Yu Wu; Yu-Chen Dai; Nian-Guang Li; Ze-Xi Dong; Ting Gu; Zhi-Hao Shi; Xin Xue; Yu-Ping Tang; Jin-Ao Duan
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

Review 4.  Advances in Multi-Functional Ligands and the Need for Metal-Related Pharmacology for the Management of Alzheimer Disease.

Authors:  Abha Sharma; Vidhu Pachauri; S J S Flora
Journal:  Front Pharmacol       Date:  2018-11-15       Impact factor: 5.810

5.  Novel Tacrine-Scutellarin Hybrids as Multipotent Anti-Alzheimer's Agents: Design, Synthesis and Biological Evaluation.

Authors:  Katarina Spilovska; Jan Korabecny; Vendula Sepsova; Daniel Jun; Martina Hrabinova; Petr Jost; Lubica Muckova; Ondrej Soukup; Jana Janockova; Tomas Kucera; Rafael Dolezal; Eva Mezeiova; Daniel Kaping; Kamil Kuca
Journal:  Molecules       Date:  2017-06-16       Impact factor: 4.411

6.  Design, synthesis and biological evaluation of novel N-phosphorylated and O-phosphorylated tacrine derivatives as potential drugs against Alzheimer's disease.

Authors:  Maja Przybyłowska; Krystyna Dzierzbicka; Szymon Kowalski; Sebastian Demkowicz; Mateusz Daśko; Iwona Inkielewicz-Stepniak
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.